Author: NKGen Biotech, Inc.

Posted Date:

April 9, 2026

NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit

NKGen Biotech, Inc.

April 9, 2026
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™

NKGen Biotech, Inc.

March 23, 2026
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026

NKGen Biotech, Inc.

March 10, 2026
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

NKGen Biotech, Inc.

January 27, 2026